| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/07/2012 | US20120141573 Cell Lines That Secrete Anti-Angiogenic Antibody-Scaffolds and Soluble Receptors and Uses Thereof |
| 06/07/2012 | US20120141498 Use of pkc isozymes for diagnosis and treatment of neuroblastoma |
| 06/07/2012 | US20120141459 Molecular targets for als and related disorders |
| 06/07/2012 | US20120141454 Methods of Use of Inhibitors of Phosphodiesterases and Modulators of Nitric Oxide, Reactive Oxygen Species, and Metalloproteinases in the Treatment of Peyronie's Disease, Arteriosclerosis and Other Fibrotic Diseases |
| 06/07/2012 | US20120141449 Albumin Fusion Proteins |
| 06/07/2012 | US20120141441 Methods and Compositions for Treatment of Muscular Dystrophy |
| 06/07/2012 | US20120141440 Foamyvirus vectors and methods of use |
| 06/07/2012 | US20120141438 Cardiac muscle repair or regeneration using bone marrow-derived stem cells |
| 06/07/2012 | US20120141437 Cardiac Muscle Regeneration Using Mesenchymal Stem Cells |
| 06/07/2012 | US20120141428 Muscle-derived cells (mdcs) for treating muscle- or bone-related injury or dysfunction |
| 06/07/2012 | US20120141422 Widespread gene delivery to the retina using systemic administration of aav vectors |
| 06/07/2012 | US20120141419 Biodegradable Linkers for Molecular Therapies |
| 06/07/2012 | US20120141415 Albumin Fusion Proteins |
| 06/07/2012 | US20120141413 Use of il-15 preparations to treat lymphopenia |
| 06/07/2012 | CA2819944A1 Modified single-stranded polynucleotide |
| 06/07/2012 | CA2819246A1 Liquid viral formulations |
| 06/07/2012 | CA2819236A1 Lyophilized viral formulations |
| 06/06/2012 | EP2460881A1 Proteoglycan degrading mutants for treatment of CNS |
| 06/06/2012 | EP2460516A2 Lipid nanoparticles for gene therapy |
| 06/06/2012 | EP2459723A1 Widespread gene delivery to the retina using systemic administration of aav vectors |
| 06/06/2012 | EP2459705A1 PRODUCTION OF ß-CELLS |
| 06/06/2012 | EP2459233A1 Adipose-derived stromal cells (asc) as delivery tool for treatment of cancer |
| 06/06/2012 | EP2459232A1 Use of microrna for treating diseases associated with a dysfunction of the cilia in multiciliated epithelial cells |
| 06/06/2012 | EP2459231A2 Rna with a combination of unmodified and modified nucleotides for protein expression |
| 06/06/2012 | EP2459230A1 Oligonucleotides inhibiting cellular migration |
| 06/06/2012 | EP2128261B1 A recombinant adenovirus comprising recombinant khp53 gene and preparation method and uses thereof |
| 06/06/2012 | EP1778296B1 Specific inhibition of autoimmunity and diseases associated with autoantigens |
| 06/06/2012 | EP1575526B1 Dna vaccines encoding heat shock proteins |
| 06/06/2012 | EP1563069B1 Compositions and systems for the regulation of genes |
| 06/06/2012 | CN1561343B Soluble T cell receptor |
| 06/06/2012 | CN102485772A Preparation method of chitosan microsphere and application of chitosan microsphere as gene vaccine vector |
| 06/06/2012 | CN102485274A Preparation method and use of poly(lactic-co-glycolic acid) (PLGA) microspheres as nucleic acid vaccine vectors |
| 06/06/2012 | CN102061310B Construction and application of human FHL1C eukaryotic expression vector |
| 06/06/2012 | CN101863965B Helicobacter pylori urease B antigenic epitope polypeptide and application thereof |
| 06/06/2012 | CN101745111B Method for restraining infiltration and metastasis of breast cancer cells by using target CCL 18 and application thereof |
| 06/06/2012 | CN101705241B Method for preparing recombined blue algae antiviral protein and application thereof |
| 06/06/2012 | CN101696413B SiRNA-935 capable of inhibiting BCLL11B expression and tumorous T cell proliferation and use thereof |
| 06/06/2012 | CN101696412B SiRNA-434 capable of inhibiting BCL11B expression and tumorous T cell proliferation and use thereof |
| 06/06/2012 | CN101659953B Anti-PCVD shRNA and design-synthesis method and application thereof |
| 06/06/2012 | CN101613702B Establishing method of non-antibiotic resistance selecting and marking system based on QAPRTase gene and application |
| 06/06/2012 | CN101507822B Reduction of dermal scarring |
| 06/06/2012 | CN101437834B Modulation of cytokine signaling regulators and applications for immunotherapy |
| 06/06/2012 | CN101060863B Modulation of neuroglia-derived BDNF in the treatment and prevention of pain |
| 06/05/2012 | US8193334 Polymer-encapsulated reverse micelles |
| 06/05/2012 | US8193333 Cancer therapy using Bcl-Xl-specific siNA |
| 06/05/2012 | US8193330 Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains |
| 06/05/2012 | US8193326 Nucleotide sequences coding oncogenic polypeptides for use in generating vaccines to prevent and treat cell proliferative disorders; genetic vaccines |
| 06/05/2012 | US8193162 Human liver regeneration associated protein and the use thereof |
| 06/05/2012 | US8193160 System for inhibiting pathogenicity in the rice-blast fungus Magnaporthe grisea |
| 06/05/2012 | US8193151 Methods for treating atrial or ventricular arrhythmias |
| 06/05/2012 | US8193146 Method of ameliorating symptom caused by mood disturbance |
| 06/05/2012 | US8192991 Methods of eliciting or boosting a cellular immune response |
| 06/05/2012 | US8192990 Buffer solution for electroporation and a method comprising the use of the same |
| 06/05/2012 | US8192989 Solid surface for biomolecule delivery and high-throughput assay |
| 06/05/2012 | US8192987 Human dental follicle stem cells and methods for obtaining |
| 06/05/2012 | US8192975 Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith |
| 06/05/2012 | US8192953 Comprising tetranectin trimerising structural element (TTSE) capable of forming a stable complex with two other TTSEs; stability; used as a carrier of other chemical entities; drug delivery |
| 06/05/2012 | US8192944 Protein fragment complementation assays for the detection of biological or drug interactions |
| 06/05/2012 | US8192935 Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer as related to MetAP2 expression |
| 06/05/2012 | US8192753 pH-sensitive cationic lipids, and liposomes and nanocapsules containing the same |
| 06/05/2012 | CA2519787C Methods of treating diabetes by blocking vegf-mediated activity |
| 06/05/2012 | CA2431207C Compositions containing inclusion complexes |
| 06/05/2012 | CA2426765C Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis |
| 06/05/2012 | CA2292882C Mutant having uracil phosphoribosyl transferase activity |
| 06/05/2012 | CA2248667C Hla-a2.1 binding peptides and their uses |
| 06/05/2012 | CA2233534C Manipulation of non-terminally differentiated cells using the notch pathway |
| 05/31/2012 | WO2012071561A2 Anti-il-6 antibodies for the treatment of anemia |
| 05/31/2012 | WO2012071554A2 Anti-il-6 antibodies for the treatment of oral mucositis |
| 05/31/2012 | WO2012071526A2 Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| 05/31/2012 | WO2012071238A2 Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
| 05/31/2012 | WO2012070639A1 Neuron-specific retrograde transport vector |
| 05/31/2012 | WO2012070621A1 Use of age-specific aptamer for treating renal disease |
| 05/31/2012 | WO2012070008A2 Recombinant proteins with a selective inactivation activity on target proteins |
| 05/31/2012 | WO2012068936A1 Use of hepatocyte nuclear factor 1α in preparation of drug for treating malignant solid tumor disease |
| 05/31/2012 | WO2012068870A1 Ternary complex, liquid containing ternary complex, preparing method and use thereof |
| 05/31/2012 | WO2012046943A3 Gene delivery system having enhanced tumor-specific expression, and recombinant gene expression regulating sequence |
| 05/31/2012 | WO2012030626A3 Design of oligonucleotide analogs as therapeutic agents |
| 05/31/2012 | WO2012027601A9 Methods targeting mir-33 micrornas for regulating lipid metabolism |
| 05/31/2012 | WO2012021735A8 Pharmaceutical products from fungal strains |
| 05/31/2012 | WO2012018877A9 Treating breast cancer with anti-il-19 antibody |
| 05/31/2012 | WO2012009711A3 Retrovirus detection |
| 05/31/2012 | WO2011157447A3 Modified parvovirus having enhanced anti-tumour efficacy |
| 05/31/2012 | US20120137379 Novel aav's and uses thereof |
| 05/31/2012 | US20120136043 Antisense oligonucleotides (odn) against smad7 and uses thereof in medical field |
| 05/31/2012 | US20120135983 DNA Damage Repair Inhibitors for the Treatment of Cancer |
| 05/31/2012 | US20120135892 siRNA targeting spleen tyrosine kinase |
| 05/31/2012 | US20120135496 Protein Belonging to the TNF Superfamily Involved in Signal Transduction, Nucleic Acids Encoding Same and Methods of Use Thereof |
| 05/31/2012 | US20120135054 Poly (Ester Ether Amide)s and Uses Thereof |
| 05/31/2012 | US20120135031 Method of enhancing an immune response |
| 05/31/2012 | US20120135020 Ttk peptides and vaccines including the same |
| 05/31/2012 | US20120135003 Anti-ilt7 antibody |
| 05/31/2012 | US20120134972 Novel Polypeptides Having Endolysin Activity And Uses Thereof |
| 05/31/2012 | US20120134969 Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| 05/31/2012 | US20120134962 Methods and compositions for tissue regeneration |
| 05/31/2012 | US20120134954 Defensin-antigen fusion proteins |
| 05/31/2012 | US20120134926 Charge-dynamic polymers and delivery of anionic compounds |
| 05/31/2012 | CA2818814A1 Anti-il-6 antibodies for the treatment of anemia |
| 05/31/2012 | CA2818813A1 Anti-il-6 antibodies for the treatment of oral mucositis |
| 05/30/2012 | EP2078531B1 Pharmaceutical compositions and methods useful for modulating angiogenesis |
| 05/30/2012 | EP1993584B1 Inhibitors of CXCR4 activity for use in the treatment of ocular disorders |